Resverlogix to chair and present at The New York Academy of Sciences' symposium "Epigenetics: Cancer & Beyond"
CALGARY, April 18, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Corporation") (TSX:RVX) is pleased to announce its participation in the upcoming symposium Epigenetics: Cancer and Beyond at The New York Academy of Sciences on Thursday, April 28, 2016, from 9am-5pm (EST) in New York City. An international assembly of biomedical investigators will convene to explore the therapeutic potential of pharmacologic modulation of the epigenome. Epigenetics – meaning 'above the genome' describes the mechanisms by which modifications are made to our biological building blocks that determine gene expression. Notably, abnormalities in the epigenome have been identified in many diseases, providing a promising new path for drug discovery.
Internationally renowned expert in the field of cancer research, Dr. Craig B Thompson, Memorial Sloan Kettering Cancer Center, will deliver the keynote address at the symposium which will be chaired by Dr. Norman Wong, Chief Scientific Officer of Resverlogix and Dr. Dominique Verhelle of Third Rock Ventures.
Academia and industry come together to share cutting edge perspectives from the field of epigenetics, in which Dr. Ewelina Kulikowski, Senior Vice President of Research & Development will present on behalf of Resverlogix. Additional speakers include: Dr. Michael Elowitz, California Institute of Technology, Dr. Keiko Ozato, National Institute of Child Health and Human Development, Dr. Roberto Pili, Indiana University School of Medicine, Dr. Patrick Trojer, Constellation Pharmaceuticals, Dr. Christopher Vakoc, Cold Spring Harbor Laboratory, Daniel Vitt, 4SC AG, and Dr. Eric Campeau, Zenith Epigenetics.
Please visit www.nyas.org to register for the symposium and/or webinar.
Resverlogix Senior Management Appointments
Resverlogix welcomes Mr. Clayton Paradis as Vice President of Investor Relations. With the addition of Mr. Paradis, Resverlogix will expand current investor relations efforts, including the enhancement of strategic relationships with market participants, along with proactive engagement of stakeholders to ensure the business and value proposition of Resverlogix is clearly defined.
Mr. Paradis brings 15 years of capital markets and investor relations experience to Resverlogix. Most recently, he led the investor relations function for one of Canada's largest energy companies with shareholders and joint venture partners geographically dispersed throughout North America, Europe and Asia. Prior to his career in investor relations, Mr. Paradis worked for two of Canada's largest financial institutions in equity research as an energy specialist, one of which was a number one ranked Royalty Trust Research Team (Brendan Wood Survey 2005). Mr. Paradis is a member of the Canadian Investor Relations Institute (CIRI) and holds an MBA – Finance from the University of Calgary and Bachelor of Management from the University of Lethbridge.
In addition, Resverlogix is pleased to announce the promotion of Dr. Ewelina Kulikowski to Senior Vice President of Research & Development. Dr. Kulikowski joined Resverlogix in 2005 and has been involved in the development of lead drug RVX-208/apabetalone from its discovery through to the IND and into clinical development. In her new role, Dr. Kulikowski will continue to build upon Resverlogix's strong scientific foundation characterizing the epigenetic mechanisms underlying disease pathology in cardiovascular disease and related indications with subsequent expansion into novel therapeutic areas.
About The New York Academy of Sciences
The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With 20,000+ Members in 100 countries around the world, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. For more information, please visit www.nyas.org.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter @Resverlogix_RVX https://twitter.com/resverlogix_rvx.
For further information please contact:
SOURCE Resverlogix Corp.